|
1
|
Lizée G, Cantu MA and Hwu P: Less yin,
more yang: Confronting the barriers to cancer immunotherapy. Clin
Cancer Res. 13:5250–5255. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stewart TJ and Abrams SI: How tumours
escape mass destruction. Oncogene. 27:5894–5903. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stewart TJ and Smyth MJ: Improving cancer
immunotherapy by targeting tumor-induced immune suppression. Cancer
Metastasis Rev. 30:125–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pierre-Audigier C, Jouanguy E, Lamhamedi
S, Altare F, Rauzier J, Vincent V, Canioni D, Emile JF, Fischer A,
Blanche S, et al: Fatal disseminated Mycobacterium smegmatis
infection in a child with inherited interferon gamma receptor
deficiency. Clin Infect Dis. 24:982–984. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sweeney KA, Dao DN, Goldberg MF, Hsu T,
Venkataswamy MM, Henao-Tamayo M, Ordway D, Sellers RS, Jain P, Chen
B, et al: A recombinant Mycobacterium smegmatis induces
potent bactericidal immunity against Mycobacterium
tuberculosis. Nat Med. 17:1261–1268. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Faassen H, Dudani R, Krishnan L and
Sad S: Prolonged antigen presentation, APC-, and CD8+ T cell
turnover during mycobacterial infection: Comparison with Listeria
monocytogenes. J Immunol. 172:3491–3500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cayabyab MJ, Hovav AH, Hsu T, Krivulka GR,
Lifton MA, Gorgone DA, Fennelly GJ, Haynes BF, Jacobs WR Jr and
Letvin NL: Generation of CD8+ T-cell responses by a recombinant
nonpathogenic Mycobacterium smegmatis vaccine vector
expressing human immunodeficiency virus type 1 Env. J Virol.
80:1645–1652. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sang M, Lian Y, Zhou X and Shan B: MAGE-A
family: Attractive targets for cancer immunotherapy. Vaccine.
29:8496–8500. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meek DW and Marcar L: MAGE-A antigens as
targets in tumour therapy. Cancer Lett. 324:126–132. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hofmann O, Caballero OL, Stevenson BJ,
Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A,
et al: Genome-wide analysis of cancer/testis gene expression. Proc
Natl Acad Sci USA. 105:20422–20427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scanlan MJ, Gure AO, Jungbluth AA, Old LJ
and Chen YT: Cancer/testis antigens: An expanding family of targets
for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gjerstorff MF, Andersen MH and Ditzel HJ:
Oncogenic cancer/testis antigens: Prime candidates for
immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Van den Eynde BJ and van der Bruggen P: T
cell defined tumor antigens. Curr Opin Immunol. 9:684–693. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gaugler B, Van den Eynde B, van der
Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F
and Boon T: Human gene MAGE-3 codes for an antigen recognized on a
melanoma by autologous cytolytic T lymphocytes. J Exp Med.
179:921–930. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Greve KB, Pøhl M, Olsen KE, Nielsen O,
Ditzel HJ and Gjerstorff MF: SSX2-4 expression in early-stage
non-small cell lung cancer. Tissue Antigens. 83:344–349. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bloom JE and McNeel DG: SSX2 regulates
focal adhesion but does not drive the epithelial to mesenchymal
transition in prostate cancer. Oncotarget. 7:50997–51011. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Greve KB, Lindgreen JN, Terp MG, Pedersen
CB, Schmidt S, Mollenhauer J, Kristensen SB, Andersen RS, Relster
MM, Ditzel HJ and Gjerstorff MF: Ectopic expression of
cancer/testis antigen SSX2 induces DNA damage and promotes genomic
instability. Mol Oncol. 9:437–449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen L, Zhou WB, Zhao Y, Liu XA, Ding Q,
Zha XM and Wang S: Cancer/testis antigen SSX2 enhances invasiveness
in MCF-7 cells by repressing ERα signaling. Int J Oncol.
40:1986–1994. 2012.PubMed/NCBI
|
|
19
|
Huang CJ, Chen RH, Vannelli T, Lee F,
Ritter E, Ritter G, Old LJ and Batt CA: Expression and purification
of the cancer antigen SSX2: A potential cancer vaccine. Protein
Expr Purif. 56:212–219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Türeci O, Sahin U, Schobert I, Koslowski
M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG and
Pfreundschuh M: The SSX-2 gene, which is involved in the t(X;18)
translocation of synovial sarcomas, codes for the human tumor
antigen HOM-MEL-40. Cancer Res. 56:4766–4772. 1996.PubMed/NCBI
|
|
21
|
Bardarov S, Kriakov J, Carriere C, Yu S,
Vaamonde C, McAdam RA, Bloom BR, Hatfull GF and Jacobs WR Jr:
Conditionally replicating mycobacteriophages: A system for
transposon delivery to Mycobacterium tuberculosis. Proc Natl
Acad Sci USA. 94:10961–10966. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu H, Crawford D, Hutchinson KR, Youtz DJ,
Lucchesi PA, Velten M, McCarthy DO and Wold LE: Myocardial
dysfunction in an animal model of cancer cachexia. Life Sci.
88:406–410. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Young SL, Murphy M, Zhu XW, Harnden P,
O'Donnell MA, James K, Patel PM, Selby PJ and Jackson AM:
Cytokine-modified Mycobacterium smegmatis as a novel
anticancer immunotherapy. Int J Cancer. 112:653–660. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo Y, Henning J and O'Donnell MA: Th1
cytokine-secreting recombinant Mycobacterium bovis bacillus
Calmette-Guérin and prospective use in immunotherapy of bladder
cancer. Clin Dev Immunol. 2011:7289302011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang H, Peng P, Miao S, Zhao Y, Mao F,
Wang L, Bai Y, Xu Z, Wei S and Shi C: Recombinant Mycobacterium
smegmatis expressing an ESAT6-CFP10 fusion protein induces
anti-mycobacterial immune responses and protects against
Mycobacterium tuberculosis challenge in mice. Scand J Immunol.
72:349–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu W, Chen L, Guo S, Wu L and Zhang J:
Intranasal administration of recombinant Mycobacterium
smegmatis inducing IL-17A autoantibody attenuates airway
inflammation in a murine model of allergic asthma. PLoS One.
11:e01515812016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bange FC, Collins FM and Jacobs WR Jr:
Survival of mice infected with Mycobacterium smegmatis
containing large DNA fragments from Mycobacterium tuberculosis.
Tuber Lung Dis. 79:171–180. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kirkin AF, Dzhandzhugazyan KN and Zeuthen
J: Cancer/testis antigens: Structural and immunobiological
properties. Cancer Invest. 20:222–236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roeder C, Schuler-Thurner B, Berchtold S,
Vieth G, Driesch Pv, Schuler G and Lüftl M: MAGE-A3 is a frequent
tumor antigen of metastasized melanoma. Arch Dermatol Res.
296:314–319. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moeller I, Spagnoli GC, Finke J, Veelken H
and Houet L: Uptake routes of tumor-antigen MAGE-A3 by dendritic
cells determine priming of naïve T-cell subtypes. Cancer Immunol
Immunother. 61:2079–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valmori D, Qian F, Ayyoub M, Renner C,
Merlo A, Gnjatic S, Stockert E, Driscoll D, Lele S, Old LJ and
Odunsi K: Expression of synovial sarcoma X (SSX) antigens in
epithelial ovarian cancer and identification of SSX-4 epitopes
recognized by CD4+ T cells. Clin Cancer Res. 12:398–404. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abate-Daga D, Speiser DE, Chinnasamy N,
Zheng Z, Xu H, Feldman SA, Rosenberg SA and Morgan RA: Development
of a T cell receptor targeting an HLA-A*0201 restricted epitope
from the cancer-testis antigen SSX2 for adoptive immunotherapy of
cancer. PLoS One. 9:e933212014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Caballero OL and Chen YT: Cancer/testis
(CT) antigens: Potential targets for immunotherapy. Cancer Sci.
100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hemminger JA, Toland AE, Scharschmidt TJ,
Mayerson JL, Guttridge DC and Iwenofu OH: Expression of
cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and
CTAG2 in myxoid and round cell liposarcoma. Mod Pathol.
27:1238–1245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vansteenkiste J, Zielinski M, Linder A,
Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T,
Jassem J, Kalofonos H, et al: Adjuvant MAGE-A3 immunotherapy in
resected non-small-cell lung cancer: Phase II randomized study
results. J Clin Oncol. 31:2396–2403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bricard G, Bouzourene H, Martinet O,
Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P,
Cerottini JC and Speiser DE: Naturally acquired MAGE-A10- and
SSX-2-specific CD8+ T cell responses in patients with
hepatocellular carcinoma. J Immunol. 174:1709–1716. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ayyoub M, Hesdorffer CS, Metthez G,
Stevanovic S, Ritter G, Chen YT, Old LJ, Speiser D, Cerottini JC
and Valmori D: Identification of an SSX-2 epitope presented by
dendritic cells to circulating autologous CD4+ T cells. J Immunol.
172:7206–7211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ayyoub M, Stevanovic S, Sahin U, Guillaume
P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC,
Rammensee HG, et al: Proteasome-assisted identification of a
SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating
metastatic melanoma. J Immunol. 168:1717–1722. 2002. View Article : Google Scholar : PubMed/NCBI
|
